6 February 2018

On January 19, during the midwinter meeting of the Dutch Association of HIV Treatment Professionals, the Martijn Verbrugge Award 2017-2018 was awarded to Pauline Bollen, PhD candidate and hospital pharmacist, within the theme of Infectious diseases and global health.

Pauline received this award for the best abstract of original research on HIV-infected patients. The title of her lecture was: The pharmacokinetics and safety of dolutegravir in HIV-infected pregnant women. The preliminary results from this study show that the plasma concentrations of the new HIV drug dolutegravir do not change significantly during pregnancy, and that the application appears to be effective and safe. These results will contribute to the next update of international guidelines for treatment of HIV-positive women. The research is part of the PANNA network that is led by Dr Angela Colbers and Prof. David Burger (www.pannastudy.com).The award is named after Martijn Verbrugge, AIDS activist and former chairman of the Dutch HIV Association who died of AIDS in 2004.

Related news items

The European Hector Research Award in HIV 2021 awarded to Angela Colbers and David Burger

2 November 2021

On Friday 29 October 2021, during the 18th European AIDS Conference in London, the Hector Research Award for the best scientific article related to clinical or epidemiological HIV research was presented to Angela Colbers and David Burger, both working in the Pharmacy of the RadboudUMC.

read more

Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis

25 January 2021

Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.

read more

Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2)

12 May 2020

In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens.

read more

The effect of pregnancy on the pharmacokinetics of dolutegravir in women living with HIV

17 March 2020

In Clinical infectious diseases RIHS researchers Pauline Bollen, Jolien Freriksen, Angela Colbers and David Burger together with researchers of the PANNA network showed that dolutegravir use in pregnancy results in effective plasma concentrations.

read more

Importance of prospective studies in pregnant and breastfeeding women living with HIV

14 March 2019

In Clinical Infectious Diseases Angela Colbers, Stein Schalkwijk and David Burger give considerations on how to effectively evaluate aspects of clinical pharmacology required for safe and effective treatment to optimize pharmacotherapy during pregnancy and breastfeeding.

read more

Beyond the scientist: Roger Brüggemann

13 November 2018

Roger, who subscribed for the national pilot academy in 1992, eventually became a hospital pharmacist and associate professor of clinical pharmacology. This summer he became a “Cinglé du Ventoux”.

read more